Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor
Megumi Oshima, Akinori Hara, Tadashi Toyama, Min Jun, Carol Pollock, Meg Jardine, Stephen Harrap, Neil Poulter, Mark E Cooper, Mark Woodward, John Chalmers, Vlado Perkovic, Muh Geot Wong, Takashi Wada
KIDNEY INTERNATIONAL REPORTS | ELSEVIER SCIENCE INC | Published : 2021
Introduction: Several circulating markers, including autoantibodies to erythropoietin receptor (anti-EPOR antibodies), have been identified as useful biomarkers in predicting diabetic kidney disease progression. However, a direct comparison of their utility is lacking. We aimed to validate and to compare the prognostic value of anti-EPOR antibodies with that of other known biomarkers, using the ADVANCE trial and its long-term follow-up, ADVANCE-ON, cohorts. Methods: In this nested case-control study from the ADVANCE trial cohort, we included 165 case participants who had the composite kidney outcome (renal replacement therapy, renal death, or doubling of serum creatinine to ≥200 μmol/l) and ..View full abstract
The biomarker work was funded by the Japan Society for the Promotion of Science Program for Fostering Globally Talented Researchers, the George Institute for Global Health (Sydney, Australia), and the Diabetes Australia Millennium Grant. The ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) was funded by the grants from the National Health and Medical Research Council (NHMRC) of Australia and Servier. The funders were not involved in the study design, data collection, data analysis, data interpretation, writing this report, or the decision to submit the report for publication. All authors had full access to all the data and had final responsibility for the decision to submit for publication.